RxDoctor Payments Data

Jody Borgman, MD

Internal Medicine · Philadelphia, PANPI 1235106378

Payments from drug & device makers

$713in general payments, 2019–2025

Across 53 payments — averaging $13.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$536
  • Johnson & Johnson$72
  • AbbVie$41
  • Gilead$33
  • Merck$17
  • Theratechnologies Inc.$14

What the payments were for

  • Food & beverage$713100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$713 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,628
Medicare patients
53
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala450$1,773,648
DovatoDolutegravir Sodium/Lamivudine436$1,274,539
GenvoyaElviteg/Cob/Emtri/Tenof Alafen78$301,439
CabenuvaCabotegravir/Rilpivirine41$252,207
OdefseyEmtricitab/Rilpiviri/Tenof Ala66$230,772
TriumeqAbacavir/Dolutegravir/Lamivudi59$213,888
TivicayDolutegravir Sodium47$131,026
PrezcobixDarunavir/Cobicistat50$130,814
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf26$116,216
DescovyEmtricitabine/Tenofov Alafenam52$111,559
OzempicSemaglutide92$84,640
IsentressRaltegravir Potassium28$54,702
TrulicityDulaglutide52$48,811
JulucaDolutegravir/Rilpivirine14$47,221
Darunavir37$45,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$33$2,186,646580 claims
Viiv Healthcare CompanyDovato, Cabenuva, Triumeq, Tivicay, Juluca$536$1,918,882597 claims
Johnson & JohnsonPrezcobix$72$130,81450 claims
MerckIsentress, Isentress Hd, Januvia$17$93,58770 claims
AbbVieCreon$41$3,31012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →